Verinomics key facts
as of Oct 2026- Operator of genomic and computational technology development firm intended to identify trait genes and develop comprehensive workflows specific to client's crop.
- Verinomics is valued at approximately $37.0M as of Oct 2026, set at its later-stage round, May 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $12.0M across 1 recorded rounds; the latest was Seed Round ($2.0M) in Dec 2018.
- Notable investors include US National Science Foundation, U.S. Department of Energy, University of California, United States Department of Agriculture, Fulcrum Global Capital — 9 tracked in total.
- Verinomics has filed 1 Form D with the SEC, most recently Jan 2019 ($2.0M sold to 2 investors).
- Status: Privately Held (backing).
Valued at $37.0M at its later-stage round, May 2025. Nothing has traded since.
- ·Watch Verinomics: the Monday email on marks, rounds and moves
Verinomics funding rounds
1 roundsVerinomics valuation
Verinomics was valued at $37 million at its later-stage round in May 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Verinomics raised?
Verinomics has raised $12 million in total; 1 of its rounds is on record. The largest on record was a $2 million seed round in Dec 2018.
Verinomics has filed 1 Form D with the SEC, most recently in Jan 2019 ($2 million sold to 2 investors).
Verinomics investors
9 investors are on record for Verinomics, including US National Science Foundation, U.S. Department of Energy, University of California and United States Department of Agriculture. The seed round in Dec 2018 drew 2 investors.
About Verinomics
Operator of genomic and computational technology development firm intended to identify trait genes and develop comprehensive workflows specific to client's crop. The company's solutions use genomics, data analytics and gene editing to offer complete integration of trait gene identification, breeding analytics, marker deployment and custom gene editing, enabling clients to accelerate product development and trait discovery.
- Sector
- Materials and Resources
- HQ
- New Haven, CT, United States
- Founded
- 2016
- Employees
- 18
- Website
- verinomics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.